Insights

In August 2026, the U.S. Food and Drug Administration (FDA) issued a revised draft guidance, Determining Whether to Submit an ANDA or a 505(b)(2) Application, providing additional clarity on one of the most strategically important questions in U.S. drug development: which abbreviated approval pathway is the most appropriate for a proposed product.

While the distinction between an Abbreviated New Drug Application (ANDA) and a 505(b)(2) application is not new, the updated draft guidance provides valuable insight into FDA's current thinking, particularly regarding product “duplicates,” formulation differences, bioavailability changes and labeling deviations.

A key message from the guidance is that products that qualify as true duplicates of an approved Reference Listed Drug (RLD) should generally be submitted through the ANDA pathway. FDA reiterates that it may refuse to file a 505(b)(2) application when the proposed product is eligible for approval as an ANDA.

The guidance also highlights situations where a 505(b)(2) pathway may be more appropriate. These include products with intentional differences from the RLD, such as modified bioavailability profiles, formulation changes requiring additional safety or efficacy data, new conditions of use, or labeling modifications that go beyond those permitted under the generic framework. In such cases, sponsors may need to provide clinical or other supporting evidence that falls outside the scope of an ANDA.

Of particular interest is FDA's increased emphasis on early engagement with the Agency. The guidance encourages developers to seek advice through Controlled Correspondence, pre-ANDA meetings, or discussions with the appropriate review division when uncertainty exists regarding the correct regulatory pathway.

For companies pursuing U.S. market entry strategies, especially those developing reformulations, complex generics, value-added medicines, or repurposed products, this draft guidance serves as an important reminder that regulatory pathway selection remains a critical determinant of development timelines, evidentiary requirements, intellectual property considerations and overall program risk. Careful regulatory assessment at an early stage can help avoid costly delays and ensure alignment with FDA expectations.

RPN will continue to monitor developments related to this draft guidance and assess their potential impact on U.S. regulatory strategies. Our experts are available to support pharmaceutical companies in defining the most appropriate development and registration pathway, minimizing regulatory risk and optimizing time-to-market for products intended for the U.S. market.